10-K: Fennec Pharmaceuticals Reports FY2024 Results: PEDMARK Sales Surge, Debt Reduced, and European Expansion Underway

Fennec Pharmaceuticals reports a 40% increase in PEDMARK net product sales for FY2024, alongside strategic debt reduction and expansion into European markets.

Summary

• Fennec Pharmaceuticals reported its financial results for the fiscal year ended December 31, 2024.
• Net product sales of PEDMARK reached $29.6 million in FY2024, a 40% increase compared to $21.3 million in 2023.
• The company saw continued momentum in the adolescent and young adult (AYA) segment and academic settings.
• Fennec completed an early repayment of $13 million of its convertible debt facility.
• The company reported a Q4 2024 EBITDA loss of $1.0 million and holds $26.6 million in cash, cash equivalents, and short-term investments.
• PEDMARQSI is now commercially available in the United Kingdom and Germany.
• In March 2024, Fennec entered into an exclusive licensing agreement with Norgine to commercialize PEDMARQSI in Europe, Australia and New Zealand.
• The licensing agreement provided Fennec with approximately $43 million up front and may provide up to approximately another $230 million in future royalties and milestone payments.
• The investigator-initiated clinical trial (STS-J01) in Japan evaluating PEDMARK fully enrolled in Q4 2024 and the results of the trial are expected in the second half of 2025 with the potential evaluation for registration of PEDMARK in Japan thereafter.
• Fennec has partnered with Inpharmus for the distribution of PEDMARK in Turkey and Gulf Cooperation Council Countries.

Sentiment

Score: 7

Explanation: The sentiment is cautiously optimistic. While the company reported a net loss, the strong sales growth of PEDMARK, debt reduction, and European expansion are positive indicators. The company's future success depends on its ability to execute its commercial strategy and manage its expenses.

Positives

• PEDMARK net product sales increased by 40% year-over-year, indicating strong market growth.
• The early repayment of $13 million in debt strengthens the company's financial position.
• The commercial launch of PEDMARQSI in the UK and Germany expands the product's global reach.
• The licensing agreement with Norgine provides a significant upfront payment and potential for future revenue.
• The company has a solid cash position of $26.6 million.

Negatives

• The company reported a net loss of $0.4 million for FY2024.
• The company reported a Q4 2024 EBITDA loss of $1.0 million.

Risks

• Regulatory and guideline developments may change.
• Scientific data and/or manufacturing capabilities may not be sufficient to meet regulatory standards or receipt of required regulatory clearances or approvals.
• Clinical results may not be replicated in actual patient settings.
• Unforeseen global instability, including political instability, or instability from an outbreak of pandemic or contagious disease, such as the novel coronavirus (COVID-19), or surrounding the duration and severity of an outbreak.
• Protection offered by the Companys patents and patent applications may be challenged, invalidated or circumvented by its competitors.
• The available market for the Companys products will not be as large as expected.
• The Companys products will not be able to penetrate one or more targeted markets.
• Revenues will not be sufficient to fund further development and clinical studies.
• Our ability to obtain necessary capital when needed on acceptable terms or at all.
• The Company may not meet its future capital requirements in different countries and municipalities.

Future Outlook

Fennec anticipates that its available capital resources will be sufficient to meet its expected working capital and capital expenditure requirements for at least the next 12 months. The company expects to see continued momentum in early 2025, particularly with adoption by academic institutions and new patient segments.

Management Comments

• '2024 marked the beginning of a foundational transformation for Fennec, setting the stage for the PEDMARK strategy that we are utilizing throughout 2025 to realize our next phase of growth.'
• 'With key management and commercial hires in Q3 and Q4, we strengthened our leadership team and with this enhanced expertise, we are now well-positioned to drive execution and excellence in the field.'
• 'We are seeing encouraging momentum in early 2025, particularly with adoption by academic institutions and new patient segments, reinforcing the value and need for PEDMARK.'
• 'With the right foundational strategies now in place, we are confident that our strong and focused execution will translate into shareholder value in 2025 and beyond.'

Industry Context

The announcement reflects a growing focus on supportive care in oncology, particularly addressing the long-term side effects of chemotherapy in pediatric patients. The partnership with Norgine highlights the value of specialized pharmaceutical companies in expanding market access for niche therapies.

Comparison to Industry Standards

• Given that PEDMARK is the first and only FDA-approved therapy for this indication, there are no direct competitors with which to compare sales figures.
• However, the company's success will be measured against the adoption rates of other orphan drugs in oncology and the ability to secure favorable reimbursement from payers.
• Companies like BioCryst Pharmaceuticals and Sarepta Therapeutics, which focus on rare diseases, could serve as benchmarks for market penetration and revenue generation.

Legal Proceedings

• The company is currently involved in patent litigation with CIPLA regarding a generic version of PEDMARK.

Stakeholder Impact

• Shareholders: Potential for increased value through revenue growth and strategic partnerships.
• Patients: Increased access to PEDMARK/PEDMARQSI for reducing ototoxicity risk.
• Employees: Continued employment and potential for career growth within the company.
• Healthcare providers: Access to a valuable treatment option for pediatric cancer patients.

Next Steps

• Continue commercialization efforts for PEDMARK in the U.S.
• Support Norgine's commercialization of PEDMARQSI in Europe, Australia, and New Zealand.
• Advance the investigator-initiated clinical trial (STS-J01) in Japan.
• Evaluate potential for registration of PEDMARK in Japan.
• Continue to partner with Inpharmus for the distribution of PEDMARK in Turkey and Gulf Cooperation Council Countries.

Key Dates

Keywords

PEDMARK, PEDMARQSI, Ototoxicity, Cisplatin, Norgine, Licensing agreement, Financial results, Commercial launch, Debt repayment, AYA oncology